MX9700851A - Adenovirus que comprende un gen codificante para la glutation peroxidasa. - Google Patents
Adenovirus que comprende un gen codificante para la glutation peroxidasa.Info
- Publication number
- MX9700851A MX9700851A MX9700851A MX9700851A MX9700851A MX 9700851 A MX9700851 A MX 9700851A MX 9700851 A MX9700851 A MX 9700851A MX 9700851 A MX9700851 A MX 9700851A MX 9700851 A MX9700851 A MX 9700851A
- Authority
- MX
- Mexico
- Prior art keywords
- coding gene
- adenovirus including
- peroxidase
- glutation
- glutation peroxidase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0065—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
- C12Y111/01—Peroxidases (1.11.1)
- C12Y111/01009—Glutathione peroxidase (1.11.1.9)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
Abstract
La presente invencion se refiere a un adenovirus recombinante defectuoso que comprende al menos una secuencia de ADN codificante para la totalidad o una parte activa de la glutation peroxidasa o de uno de sus derivados. La misma se refiere igualmente a su utilizacion en la terapia y a las composiciones farmacéuticas correspondientes.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9409982A FR2723588B1 (fr) | 1994-08-12 | 1994-08-12 | Adenovirus comprenant un gene codant pour la glutathion peroxydase |
| PCT/FR1995/001002 WO1996005320A1 (fr) | 1994-08-12 | 1995-07-26 | Adenovirus comprenant un gene codant pour la glutathion peroxydase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX9700851A true MX9700851A (es) | 1997-04-30 |
Family
ID=9466290
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX9700851A MX9700851A (es) | 1994-08-12 | 1995-07-26 | Adenovirus que comprende un gen codificante para la glutation peroxidasa. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20010029249A1 (es) |
| EP (1) | EP0775213B1 (es) |
| JP (1) | JPH10504193A (es) |
| AT (1) | ATE293700T1 (es) |
| AU (1) | AU710727B2 (es) |
| CA (1) | CA2197235C (es) |
| DE (1) | DE69534165T2 (es) |
| FI (1) | FI970579L (es) |
| FR (1) | FR2723588B1 (es) |
| IL (1) | IL114904A0 (es) |
| MX (1) | MX9700851A (es) |
| NO (1) | NO970282L (es) |
| WO (1) | WO1996005320A1 (es) |
| ZA (1) | ZA956678B (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6814962B1 (en) * | 1994-06-02 | 2004-11-09 | Aventis Pharma S.A. | Recombinant viruses and their use for treatment of atherosclerosis and other forms of coronary artery disease and method, reagent, and kit for evaluating susceptibility to same |
| US6544523B1 (en) | 1996-11-13 | 2003-04-08 | Chiron Corporation | Mutant forms of Fas ligand and uses thereof |
| US6200799B1 (en) * | 1997-06-03 | 2001-03-13 | University Of Lausanne | Somatic gene therapy to suppress secondary cataract formation following eye surgery |
| DE69841807D1 (de) | 1997-11-06 | 2010-09-16 | Novartis Vaccines & Diagnostic | Neisseriale antigene |
| DE69941567D1 (de) | 1998-01-14 | 2009-12-03 | Novartis Vaccines & Diagnostic | Antigene aus neisseria meningitidis |
| DE69937419T2 (de) | 1998-05-01 | 2008-07-24 | Novartis Vaccines and Diagnostics, Inc., Emeryville | Neisseria Meningitidis Antigene und Zusammenstellungen |
| US7368261B1 (en) | 1999-04-30 | 2008-05-06 | Novartis Vaccines And Diagnostics Srl | Conserved Neisserial antigens |
| GB9911683D0 (en) | 1999-05-19 | 1999-07-21 | Chiron Spa | Antigenic peptides |
| GB9916529D0 (en) | 1999-07-14 | 1999-09-15 | Chiron Spa | Antigenic peptides |
| PT2275554E (pt) | 1999-10-29 | 2015-06-26 | Novartis Vaccines & Diagnostic | Péptidos antigénicos de neisseria |
| EP2275129A3 (en) | 2000-01-17 | 2013-11-06 | Novartis Vaccines and Diagnostics S.r.l. | Outer membrane vesicle (OMV) vaccine comprising N. meningitidis serogroup B outer membrane proteins |
| AU1412702A (en) | 2000-10-27 | 2002-05-06 | Chiron Spa | Nucleic acids and proteins from streptococcus groups a and b |
| GB0107661D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Staphylococcus aureus |
| GB0107658D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Streptococcus pneumoniae |
| ES2312649T3 (es) | 2001-12-12 | 2009-03-01 | Novartis Vaccines And Diagnostics S.R.L. | Inmunizacion frente a chlamydia trachomatis. |
| AU2002357311A1 (en) * | 2001-12-18 | 2003-06-30 | Johns Hopkins University School Of Medicine | Prevention and treatment of oxidative stress disorders by glutathione and phase ii detoxification enzymes |
| GB0308198D0 (en) | 2003-04-09 | 2003-05-14 | Chiron Srl | ADP-ribosylating bacterial toxin |
| PT1736541E (pt) | 2004-03-29 | 2013-01-31 | Galpharma Co Ltd | Nova proteína galectina 9 modificada e sua utilização |
| ATE522541T1 (de) | 2006-06-09 | 2011-09-15 | Novartis Ag | Bakterielle adhäsine konformere |
| US10947500B2 (en) * | 2014-06-27 | 2021-03-16 | Angiocrine Bioscience, Inc. | Neural cells expressing adenovirus E4ORF1, and methods of making and using the same |
| CN110108883A (zh) * | 2018-10-27 | 2019-08-09 | 广州呼吸健康研究院 | 用于筛选与靶治疗ards患者的msc精准医学的标志物组合 |
| WO2025101837A1 (en) * | 2023-11-10 | 2025-05-15 | Eccletech Llc | Biological devices and methods of using the same for detection of different types of cancer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1988007541A1 (en) * | 1987-04-01 | 1988-10-06 | Chiron Corporation | Polynucleotide construct encoding a polypeptide substantially similar to human glutathione peroxidase |
| US5082670A (en) * | 1988-12-15 | 1992-01-21 | The Regents Of The University Of California | Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system |
| JPH0327289A (ja) | 1989-06-22 | 1991-02-05 | Toyo Jozo Co Ltd | 新規な血漿型グルタチオン・パーオキシダーゼ遺伝子およびその用途 |
| WO1993020195A1 (en) * | 1992-04-01 | 1993-10-14 | Fox Chase Cancer Center | Method and recombinant cells for providing increased resistance of hematopoietic progenitor cells to toxicity of chemotherapeutic agents |
| AU7019494A (en) | 1993-05-20 | 1994-12-20 | Baylor College Of Medicine | Genetic therapy for cardiovascular disease |
| US5543328A (en) * | 1993-08-13 | 1996-08-06 | Genetic Therapy, Inc. | Adenoviruses having modified fiber proteins |
| US7252989B1 (en) * | 1994-04-04 | 2007-08-07 | Board Of Regents, The University Of Texas System | Adenovirus supervector system |
-
1994
- 1994-08-12 FR FR9409982A patent/FR2723588B1/fr not_active Expired - Fee Related
-
1995
- 1995-07-26 FI FI970579A patent/FI970579L/fi not_active IP Right Cessation
- 1995-07-26 DE DE69534165T patent/DE69534165T2/de not_active Expired - Lifetime
- 1995-07-26 AU AU30826/95A patent/AU710727B2/en not_active Ceased
- 1995-07-26 US US08/776,786 patent/US20010029249A1/en not_active Abandoned
- 1995-07-26 JP JP8507057A patent/JPH10504193A/ja active Pending
- 1995-07-26 WO PCT/FR1995/001002 patent/WO1996005320A1/fr not_active Ceased
- 1995-07-26 AT AT95926429T patent/ATE293700T1/de not_active IP Right Cessation
- 1995-07-26 CA CA2197235A patent/CA2197235C/fr not_active Expired - Fee Related
- 1995-07-26 MX MX9700851A patent/MX9700851A/es unknown
- 1995-07-26 EP EP95926429A patent/EP0775213B1/fr not_active Expired - Lifetime
- 1995-08-10 IL IL11490495A patent/IL114904A0/xx unknown
- 1995-08-10 ZA ZA956678A patent/ZA956678B/xx unknown
-
1997
- 1997-01-22 NO NO970282A patent/NO970282L/no not_active Application Discontinuation
-
2004
- 2004-02-02 US US10/768,635 patent/US7241591B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| FR2723588B1 (fr) | 1996-09-20 |
| DE69534165T2 (de) | 2006-03-09 |
| DE69534165D1 (de) | 2005-05-25 |
| WO1996005320A1 (fr) | 1996-02-22 |
| FI970579A7 (fi) | 1997-02-11 |
| EP0775213A1 (fr) | 1997-05-28 |
| JPH10504193A (ja) | 1998-04-28 |
| US20010029249A1 (en) | 2001-10-11 |
| AU710727B2 (en) | 1999-09-30 |
| US7241591B2 (en) | 2007-07-10 |
| FR2723588A1 (fr) | 1996-02-16 |
| FI970579A0 (fi) | 1997-02-11 |
| ATE293700T1 (de) | 2005-05-15 |
| IL114904A0 (en) | 1995-12-08 |
| NO970282D0 (no) | 1997-01-22 |
| EP0775213B1 (fr) | 2005-04-20 |
| FI970579L (fi) | 1997-02-11 |
| NO970282L (no) | 1997-01-22 |
| ZA956678B (en) | 1996-03-20 |
| CA2197235A1 (fr) | 1996-02-22 |
| AU3082695A (en) | 1996-03-07 |
| US20040175363A1 (en) | 2004-09-09 |
| CA2197235C (fr) | 2010-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX9700851A (es) | Adenovirus que comprende un gen codificante para la glutation peroxidasa. | |
| MX9606327A (es) | Adenovirus que comprende un gen que codifica para un superoxido dismutasa. | |
| ES2042693T5 (es) | Formulaciones de proteinas plasmaticas y recombinantes en medios de baja potencia ionica. | |
| ES2120036T3 (es) | Virus recombinantes y su utilizacion en terapia genetica. | |
| BR9608449A (pt) | Vìrus recombinante defeituoso, adenovìrus, uso de um vìrus, e, composição farmacêutica. | |
| DE3856265D1 (de) | Varianten des pankreatischen Rinder-Trypsininhibitors, deren Herstellung und Verwendung | |
| NO962791L (no) | Preparater inneholdende nukleinsyrer, deres fremstilling og anvendelse | |
| UA66417C2 (en) | Recombinant adenovirus affecting canines, pharmaceutical composition | |
| ES2053676T3 (es) | Formulacion de proteinas plasmaticas y recombinantes en medios de fuerza ionica elevada. | |
| TR200200938T2 (tr) | CCR5 modülatörleri olarak piperidinler | |
| FI971613A7 (fi) | Defektiivisiä adenoviruksia, jotka käsittävät terapeuttisen geenin ja immunoprotektiivisen geenin | |
| ATE179429T1 (de) | Cytokine dämpfende substanzen | |
| PT797676E (pt) | Vector adenoviral recombinante e metodos de utilizacao | |
| BR9807686A (pt) | Mostrador | |
| NO910982L (no) | Uratoksydase-aktivt protein, rekombinant gen som koder for det, ekspresjonsvektor, mikroorganismer og transformerteceller. | |
| BR9807618A (pt) | Análogo de fator xdelta, dna recombinante codificante para um análogo de fator xdelta, células transformadas, preparação, uso da mesma, e, processos para produzir uma preparação contendo análogo de fator xdelta recombinante purificado e análogo de fator xa. | |
| DK0932689T3 (da) | Assay for homocystein og homocysteindesulphurase fra protozo-trichomonas vaginalis | |
| HUP0002985A2 (hu) | Glicirrizinsavat és legalább egy antivirális hatású proteint tartalmazó vírusellenes gyógyszerkészítmény | |
| ATE250129T1 (de) | Modifizierte peptidsynthetasen, und deren verwendung in der nicht-ribosomalen herstellung von peptiden | |
| ES2181710T3 (es) | Adenovirus recombinantes y su utilizacion en terapia genica para el tratamiento de las patologias oculares. | |
| MX9700298A (es) | Adenovirus que comprende un gen que codifica para una no sintasa. | |
| ATE371737T1 (de) | Proteaseresistente flint-analoge | |
| ATE407217T1 (de) | Hochexpression und herstellung von recombinanter s-adenosyl homocysteinase mit hochspezifischer aktivität und verbesserte testverfahren für s- adenosylmethionine (sam) | |
| DE60044038D1 (de) | Xylosyltransferase und isoformen | |
| FI973104A0 (fi) | Rekombinantti-DNA, joka on valmistettu integroimalla sellainen DNA, joka koodaa myosiinin raskasketju-SM1-isoformiproteiinia vektori-DNA:ssa, sekä tämän rekombinantti-DNA:n sisältävät mikro-organismi ja arterioskleroosilääke |